Lifecore Biomedical (LFCR) presents deeply negative liquidation recovery to common equity as of March 31, 2026. Total assets are $225.5M, but under liquidation haircuts the recoverable asset pool shrinks materially: cash of $20.8M recovers at 100%; accounts receivable (net, implied ~$17.4M after $1.0M allowance) recovers at ~90-95% (~$16-17M); inventory of $28.2M recovers at 60% (~$17M); PP&E gross $186.1M less accumulated depreciation $60.6M yields net book value of $125.5M, recoverable at 50-70% (~$63-88M); goodwill $13.9M and other intangibles carry zero liquidation value; other noncurrent assets $8.5M are largely illiquid at zero. Total haircut asset recovery is approximately $120-140M. Against this, face-value liabilities total $204.7M on the balance sheet, but that figure excludes temporary equity. The Redeemable Convertible Preferred Stock carries an aggregate liquidation preference of $49.3M (ahead of common equity per certificate terms) with redemption rights commencing June 29, 2026. The debt principal stack stands at $200.1M face value (term loan with Alcon Research $188.6M, leaseback liability $5.6M, finance lease $5.8M), though the balance sheet net of discount shows $148.7M. Under liquidation, face value governs: $200.1M debt principal plus the $29.7M embedded debt derivative liability (a separate noncurrent liability at fair value) plus current liabilities of $20.5M, plus other noncurrent liabilities $6.7M, plus the $49.3M preferred liquidation preference together consume all asset recovery and leave common equity deeply negative. MFFAIS confirms CLV of -$154M. Since the prior filing (Q ended September 30, 2025), the Alcon term loan principal has grown from $179.6M to $188.6M purely from PIK interest accretion ($4.5M in the current quarter alone), the debt derivative liability increased from $26.6M to $29.7M reflecting a higher modeled discount rate (17.6% to 21.1%) tied to credit deterioration, and revenue declined sharply 34% versus the prior comparable period, compressing gross margin from 28% to 19.2% and increasing operating losses. The preferred redemption trigger date of June 29, 2026 is imminent, and internally generated cash is explicitly stated to be insufficient to fund redemptions. Ongoing material weakness in internal controls (not yet remediated as of March 31, 2026) adds reporting risk. Filing discusses Alcon's manufacturing capacity maintenance obligation through 2033 and guaranteed purchase commitments through 2031 in MD&A but these are not separately tagged in XBRL. A $15M litigation claim (new complaint filed June 30, 2025) is disclosed in the contingencies note but not accrued and not separately tagged.
▼ Community Notes